Home
Resources
Publications
Overlapping Demyelinating Syndromes and anti-N-methyl-D-aspartate Receptor Encephalitis

Overlapping Demyelinating Syndromes and anti-N-methyl-D-aspartate Receptor Encephalitis

Maarten J Titulaer, Romana Höftberger, Takahiro Iizuka, Frank Leypoldt, Lindsey McCracken, Tania Cellucci, Leslie A Benson, Huidy Shu, Takashi Irioka, Makito Hirano, Gagandeep Singh, Alvaro Cobo Calvo, etc.

Ann Neurol. 2014 Mar;75(3):411-28.

PMID: 24700511

Abstract:

Objective:
To report the clinical, radiological, and immunological association of demyelinating disorders with anti-Nmethyl- D-aspartate receptor (NMDAR) encephalitis.
Methods:
Clinical and radiological analysis was done of a cohort of 691 patients with anti-NMDAR encephalitis. Determination of antibodies to NMDAR, aquaporin-4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed using brain immunohistochemistry and cell-based assays.
Results:
Twenty-three of 691 patients with anti-NMDAR encephalitis had prominent magnetic resonance imaging (MRI) and/or clinical features of demyelination. Group 1 included 12 patients in whom anti-NMDAR encephalitis was preceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4 anti-AQP4 positive) or brainstem or multifocal demyelinating syndromes (7 cases, all anti-MOG positive). Group 2 included 11 patients in whom anti-NMDAR encephalitis occurred simultaneously with MRI and symptoms compatible with demyelination (5 AQ4 positive, 2 MOG positive). Group 3 (136 controls) included 50 randomly selected patients with typical anti-NMDAR encephalitis, 56 with NMO, and 30 with multiple sclerosis; NMDAR antibodies were detected only in the 50 anti-NMDAR patients, MOG antibodies in 3 of 50 anti-NMDAR and 1 of 56 NMO patients, and AQP4 antibodies in 48 of 56 NMO and 1 of 50 anti-NMDAR patients (p<0.0001 for all comparisons with Groups 1 and 2). Most patients improved with immunotherapy, but compared with anti-NMDAR encephalitis the demyelinating episodes required more intensive therapy and resulted in more residual deficits. Only 1 of 23 NMDAR patients with signs of demyelination had ovarian teratoma compared with 18 of 50 anti-NMDAR controls (p50.011).
Interpretation:
Patients with anti-NMDAR encephalitis may develop concurrent or separate episodes of demyelinating disorders, and conversely patients with NMO or demyelinating disorders with atypical symptoms (eg, dyskinesias, psychosis) may have anti-NMDAR encephalitis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP70476630	AQ4		70476-63-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: